Inflammatory Bowel Diseases Pocket Guide
Total Page:16
File Type:pdf, Size:1020Kb
Virtual Inflammatory Bowel Diseases Pocket Guide ©”The circle Bridge” by Maria Eklind 16th Congress of ECCO Virtual July 2-3 & 8-10, 2021 www.ecco-ibd.eu ECCO’21 Virtual Congress | About ECCO Key Dates June 28, 2021 ECCO‘21 Virtual Congress Platform opens July 2-3, 2021 Educational Programme July 8-10, 2021 16th Congress of ECCO 2021: Scientific Programme ECCO IBD APP ECCO Congress Office July 2, 2021 07:00 - 19:00 CEST Download July 3, 2021 07:00 - 17:00 CEST now! July 5-7, 2021 09:00 - 17:00 CEST July 8, 2021 07:00 - 19:00 CEST July 9, 2021 07:00 - 19:00 CEST July 10, 2021 07:00 - 16:00 CEST About ECCO ECCO strives for optimisation of care for patients with IBD in all aspects. As part of this mission ECCO adopts and further all efforts that lead to an improvement of the use of current therapies and procedures. Main aims include the development of guidelines with highest possible methodology and content quality and joint efforts to define better and more valid outcome parameters for the therapy of IBD. Further aspects of the mission include the promotion of specialist, postgraduate education in IBD, as well as scientific projects in IBD. Such promotion can include intellectual input, funding and joint The World of ECCO training using an ECCO defined curriculum. ECCO’s visibility will always be as an organisation and not as the individuals making up in your pocket ECCO. With all its activities the name of ECCO will stand in the world Features and Benefits: of gastroenterology for the highest possible level in quality and full • Listen to Audio Podcasts and impartiality in the results. watch Talking Heads on the go • Discover the e-Guide ECCO Office • Access ECCO News at any time • Find more ECCO Initiatives at one glance Ungargasse 6/13 • Stay up-to-date in the IBD World 1030 Vienna, Austria Phone: +43-(0)1-710 22 42 • Explore the ECCO’21 Congress Fax: +43-(0)1-710 22 42-001 E-Mail: [email protected] Available in App Stores free of charge: Web: www.ecco-ibd.eu 2 16th Congress of ECCO - European Crohn‘s and Colitis Organisation Scientific programme day by day “IBD precise” 10: Are we safer with biologics or 14:25 - 14:40 small-molecules? “IBD precise” E. Louis, Liège, Belgium 11: OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the Thursday, July 8, 2021 14:40 - 14:50 prospective urban rural epidemiology (PURE) study: Scientific programme day by day A prospective cohort study N. Narula, Hamilton, Canada Industry Sponsored Satellite Symposia 12: OP06: 5-aminosalicylates are not associated 11:00 - 12:00 1a, 1b &1c with adverse outcomes in Inflammatory Bowel 1: Opening 14:50 - 15:00 Disease patients with COVID-19: Analysis from an 12:15 - 12:30 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France international registry R. Ungaro, New York, United States Scientific Session 1: Sophisticated strategies within reach 13: Are surgical interventions really more harmful 12:30 - 13:45 P. Irving, London, United Kingdom 15:00 - 15:15 than medical treatment? S. Vermeire, Leuven, Belgium O. Faiz, Harrow, United Kingdom 2: Head to head trials 15:15- 15:30 Break 12:30 - 12:45 S. Ghosh, Cork, Ireland Scientific Session 3: Hot and (almost) happening 3: OP01: Comparison of fecal transplantation, 15:30 - 16:35 J. Burisch, Hvidovre, Denmark fecal transplantation with the novel UC diet or C. Maaser, Lüneburg, Germany the UC diet alone for Refractory Mild to Moderate 15:30 - 15:45 14: How machine learning will affect IBD treatment 12:45 - 12:55 Active Ulcerative Colitis: The CRAFT UC randomized S. Ennis, Southampton, United Kingdom controlled trial 15: Artificial intelligence: A strategic alliance A. Levine, Holon, Israel 15:45 - 16:00 between the machine and the endoscopist 4: Switching from IV to SC: Benefits beyond merely P. Bossuyt, Bonheiden, Belgium 12:55 - 13:10 convenience? 16: OP07: Artificial intelligence surpasses S. Schreiber, Kiel, Germany 16:00 - 16:10 gastrointestinal experts in the classification of 5: OP02: Ustekinumab versus adalimumab for endoscopic severity among Ulcerative Colitis B. Lo, Hvidovre, Denmark 13:10 - 13:20 induction and maintenance therapy in Moderate-to- Severe Crohn’s Disease: The SEAVUE study 17: OP08: Automatic detection of enteric ulcers and P. Irving, London, United Kingdom 16:10 - 16:20 erosions in capsule endoscopy using a convolutional 6: OP03: Anti-SARS-CoV2 antibody responses are neural network M. Saraiva, Porto, Portugal 13:20 - 13:30 attenuated in patients with Inflammatory Bowel Disease treated with infliximab 18: How to set-up a virtual clinic? N. Kennedy, Exeter, United Kingdom 16:20 - 16:35 M. Pierik, Maastricht, The Netherlands 7: Combining biologics: Pros and cons 16:35- 16:45 Break 13:30 - 13:45 D. Rubin, Chicago, United States 16:45 - 17:45 Digital Oral Presentations (Sessions 1-5) 13:45 - 14:00 Break 17:45- 17:55 Break Scientific Session 2: Safety first? 14:00 - 15:15 M. Adamina, Winterthur, Switzerland 17:55 - 18:55 Industry Sponsored Satellite Symposia L. Lopetuso, Rome, Italy 2a , 2b & 2c 8: When do we really know the safety profile of a 14:00 - 14:15 drug? J. Rahier, Yvoir, Belgium 9: OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study 14:15 - 14:25 and phase 3 SELECTIONLTE long-term extension study S. Schreiber, Kiel, Germany 4 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 5 Scientific programme day by day “IBD precise” Friday, July 9, 2021 10:15 - 10:30 27: The future of radiology for IBD Scientific programme day by day A. Laghi, Rome, Italy 10:30 - 10:45 Break Industry Sponsored Morning Satellite Symposia Scientific Session 5: The young and the old 07:15 - 08:15 3a, 3b & 3c 10:45 - 12:00 T. Raine, Cambridge, United Kingdom P. Van Rheenen, Groningen, The Netherlands Scientific Session 4.1.: Next generation diagnostics 08:30 - 09:20 T. Kucharzik, Lüneburg, Germany 28: Lessons from paediatric IBD – early disease N. Yassin, Birmingham, United Kingdom 10:45 - 11:00 intervention, nutrition, genetic testing J. Van Limbergen, Amsterdam, The Netherlands 19: What histology can tell us: Are we speaking the same language? 29: OP15: Cyclic exclusive enteral nutrition to 08:30 - 08:50 R. Feakins, London, United Kingdom maintain longterm drug-free remission in Paediatric F. Magro Dias, Porto, Portugal 11:00 - 11:10 Crohn’s Disease: the CD HOPE study of the GETAID pédiatrique 20: OP09: Patient reported outcomes reflect B. Pigneur Arnaud, Paris, France 08:50 - 09:00 histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study 11:10 - 11:25 30: Drug safety in the elderly patients with IBD B. Verstockt, Leuven, Belgium T. Lobatón Ortega, Ghent, Belgium 21: OP10: Response to biologics in IBD patients 31: OP16: Characterization of the Clinical Features assessed by Computerized image analysis of and Outcomes of Paediatric Patients with Isolated 09:00 - 09:10 Probe Based Confocal Laser Endomicroscopy with 11:25 - 11:35 Colonic Crohn’s Disease: A Multi-center Study from molecular labeling and gene expression profiling the Porto Group of ESPGHAN M. Iacucci, Birmingham, United Kingdom D. Shouval, Petah Tiqwa, Israel 22: OP11: Longitudinal profiling of mucosal 32: OP17: Impact of phenotypic and genetic factors immune cell composition using multiplex 11:35 - 11:45 on Crohn’s Disease evolution in a cohort of 13,926 09:10 - 09:20 immunohistochemistry identifies drug- and patients response-specific patterns in Ulcerative Colitis Q. Zhang, Cambridge, United Kingdom V. Volk, Hannover, Germany 11:45 - 12:00 33: Body image and sexuality 09:20 - 09:30 Break P. Tozer, London, United Kingdom Scientific Session 4.2.: Next generation diagnostics 12:00 - 12:10 Break 09:30 - 10:30 T. Kucharzik, Lüneburg, Germany Industry Sponsored Lunch Satellite Symposia LS1, N. Yassin, Birmingham, United Kingdom 12:10 - 12:50 LS2, LS3 & LS4 09:30 - 09:45 23: Fluorescence in IBD surgery 12:50 - 13:00 Break M. Slooter, Amsterdam, The Netherlands Scientific Session 6: Bottoms behaving badly 24: OP12: Blood proteins related to 13:00 - 14:15 A. Armuzzi, Rome, Italy immunoregulation or cellular junctions reveal Z. Zelinkova, Bratislava, Slovakia distinct biological profiles associated with the risk of 09:45 - 09:55 34: New surgical approaches for perianal disease short-term versus mid/long-term relapse in Crohn’s 13:00 - 13:15 P. Kotze, Curitiba, Brazil Disease patients stopping infliximab N. Pierre, Liège, Belgium 35: OP18: Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction 25: OP13: Mucosal organoids capture Innate 13:15 - 13:25 treatment versus anti-TNF without surgery (PISA II) - Lymphoid Cells (ILC) tissue-specific development and A patient preference RCT 09:55 - 10:05 reveal that Inflammatory Bowel Disease-associated E. Meima-van Praag, Amsterdam, The Netherlands ILC modulate intestinal remodelling J. Neves, London, United Kingdom 36: Looking beyond anti-TNF 13:25 - 13:40 S. Vavricka, Zurich, Switzerland 26: OP14: Extracellular RNAs as liquid biopsy non- 37: OP19: Disease course and treatment outcomes 10:05 - 10:15 invasive biomarker in IBD of early resected Crohn‘s Disease patients: A Danish B. Verstockt, Leuven, Belgium 13:40 - 13:50 nationwide cohort study from 1997 to 2015 M. Zhao, Hvidovre, Denmark 6 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 7 Scientific programme day by day “IBD precise” 47: OP26: Risankizumab induces early clinical Friday, July 9, 2021, cont.